VX-702

Catalog No.S6005

For research use only.

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

VX-702 Chemical Structure

CAS No. 745833-23-2

Selleck's VX-702 has been cited by 34 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Other p38 MAPK Products

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NGfmS|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFE2PDNizszN Mn\vV2FPT0WU
human NCI-H720 cell M1rxRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPj[XBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1? NHjQOYRUSU6JRWK=
JVM-2 cell NXG2W4FtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX24SXJoUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> MX3TRW5ITVJ?
human NCI-H69 cell NHKzbYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6QTRzIN88US=> MXjTRW5ITVJ?
human BV-173 cell NUPD[4V[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEe3OZVKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|OE[g{txO M1HuPXNCVkeHUh?=
human KU812 cell NEPuZWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlfqTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN NHXFRZNUSU6JRWK=
human DU-145 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkGwTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=> NIrNZYZUSU6JRWK=
KARPAS-45 cell Mo\oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;CdZJUUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= NXXrUG1MW0GQR1XS
human AGS cell NH2xTXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHMTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NlUyKM7:TR?= MYHTRW5ITVJ?
human MOLT-13 cell NUPvepJTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2QThzIN88US=> M2iyTXNCVkeHUh?=
human NCI-H209 cell MnLIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEf6[ldKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zN{W4JO69VQ>? NVHjfJdGW0GQR1XS
human CTV-1 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUHJTFdkUW6qaXLpeIlwdiCxZjDoeY1idiCFVG[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTh|OEmg{txO MVrTRW5ITVJ?
LU-139 cell NWTBRVhST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{LRRmlvcGmkaYTpc44hd2ZiaIXtZY4hVFVvMUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQTR|NTFOwG0> NV;tbIlzW0GQR1XS
ML-2 cell MnPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1i1dWlvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI3PjFizszN MXzTRW5ITVJ?
human K5 cell MoLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MkmxO{DPxE1? MljEV2FPT0WU
human SBC-1 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{LXNmlvcGmkaYTpc44hd2ZiaIXtZY4hW0KFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PjJizszN NVe2epNoW0GQR1XS
human COR-L88 cell NHe5b3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWfvO5pOUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFg5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{S4JO69VQ>? MoPPV2FPT0WU
human KY821 cell NUfONGtqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkO3TY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k3ODNizszN M1XRfXNCVkeHUh?=
human HCC2218 cell NFPHXo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmq3TY5pcWKrdHnvckBw\iCqdX3hckBJS0N{MkG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTd{ODFOwG0> NYj1W45NW0GQR1XS
human ECC10 cell NWnvUFhXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWmxVlM4UW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV|OEmg{txO MmnlV2FPT0WU
human EW-3 cell NFjLVVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWezN4M{UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZzMTFOwG0> NWjMSYs6W0GQR1XS
human EW-18 cell MlrWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHHIbnRKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PDZ5OTFOwG0> NHvaeYlUSU6JRWK=
human UACC-257 cell Ml;iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODN{NjFOwG0> NW[5WFhQW0GQR1XS
human G-361 cell M{PjTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGOy[2xKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41QTVzOTFOwG0> MmTvV2FPT0WU
human HMV-II cell NUS1W|BUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHTOcY1KdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO MVXTRW5ITVJ?
human DEL cell M{Tq[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIP3XGpKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlA4ODRizszN NXrXZXNYW0GQR1XS
human IGROV-1 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> NGrUV2tUSU6JRWK=
human SK-OV-3 cell NFjo[HpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnuzTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk43OTZ7NzFOwG0> NFnmRWZUSU6JRWK=
human LAMA-84 cell NHLoXJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPKZ5RKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjdzMki0JO69VQ>? NIGwPYdUSU6JRWK=
human NCI-H510A cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTkU|JKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVExSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUK1NlYh|ryP Ml7HV2FPT0WU
human CP66-MEL cell Ml\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLBNYdKdmirYnn0bY9vKG:oIHj1cYFvKEOSNk[tUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57M{W1PUDPxE1? M4KyfnNCVkeHUh?=
human HAL-01 cell M4PseWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1i2fGlvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPzlzODFOwG0> MXzTRW5ITVJ?
human RS4-11 cell  MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoDBTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcxPTd|IN88US=> NFXGeGVUSU6JRWK=
human RPMI-8226 cell NIDud5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJ|N{[g{txO MUDTRW5ITVJ?
human NCI-H82 cell MonPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfXbHRQUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56OUOwOUDPxE1? Ml7JV2FPT0WU
human NY cells M4qwU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1ztc2lvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkK3OlM4KM7:TR?= NWfpdYtCW0GQR1XS
human MDA-MB-361 cell NV;aRlVzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnVTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52M{G1PEDPxE1? M2\MPXNCVkeHUh?=
human MOLT-4 cell MorpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\TbVBRUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? MlLLV2FPT0WU
human DU-4475 cell NEm1N4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LwNWlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODV3NkWg{txO NFPnPZlUSU6JRWK=
human ESS-1 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXuVZFKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zQTF5OTFOwG0> M3L3THNCVkeHUh?=
human NCI-H1299 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MliwTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGyPVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV|MEOzJO69VQ>? Mk\OV2FPT0WU
human COLO-684 cell NVj2WFU3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3X5fGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV6MU[1JO69VQ>? MmTpV2FPT0WU
human MV-4-11 cell M{DtV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUfoSVJKUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS55MUG5PUDPxE1? MmnkV2FPT0WU
human D-542MG cell M2W2Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1r4NmlvcGmkaYTpc44hd2ZiaIXtZY4hTC13NELNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOzl{N{Kg{txO MmTTV2FPT0WU
human A4-Fuk cell MnfjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVn4RolIUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|Nk[yJO69VQ>? NX64dWpFW0GQR1XS
human HL-60 cell NVLtOFl4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz61NlIyOiEQvF2= MnK0V2FPT0WU
human NCI-H526 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;wWXFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py53OUiwNUDPxE1? NYS3Wo9FW0GQR1XS
human L-363 cell M{PpUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz63PVI2OiEQvF2= M1TuV3NCVkeHUh?=
human A388 cell MofCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkLmTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64NFM5PCEQvF2= M3PmcHNCVkeHUh?=
human MS-1 NFzubJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vOZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVVNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFM1PjVizszN MmOyV2FPT0WU
human JAR cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnfETY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki0PVI{KM7:TR?= Mkn3V2FPT0WU
human TI-73 cell NFexc2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUDtOVBDUW6qaXLpeIlwdiCxZjDoeY1idiCWST23N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvODZ{MjFOwG0> MUTTRW5ITVJ?
human CTB-1 cell MoDPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD6xO|gzPSEQvF2= NWfG[ZFIW0GQR1XS
human SK-NEP-1 cell NFrLXlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXfIWnA4UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkOwN|gh|ryP NVjpXGdnW0GQR1XS
human HT-29 cell M3TCe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\CeWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{46OTFzIN88US=> Mn7PV2FPT0WU
human NCI-H1092 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUXO[VNnUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExQTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND6zNVgh|ryP M2TaNXNCVkeHUh?=
human KMOE-2 cell NYTsUGZpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3vBV2lvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjF5ODFOwG0> M3mx[3NCVkeHUh?=
human EM-2 cell MkHNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFQyKM7:TR?= NVHGN49XW0GQR1XS
human RT-112 cell M13Jdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlznTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4{QTh2IN88US=> MYrTRW5ITVJ?
human DB cell MmTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW[1V3dZUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlg2OTNizszN NUC3OmpHW0GQR1XS
human NCI-H1770 cell NVjk[opCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 NIfJPWtUSU6JRWK=
human CAL-54 cell NHnD[IFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;WfXZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> NYnJZYlRW0GQR1XS
human NB14 cell NXvKXFlzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGS3[ZhKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{43Ozl3IN88US=> M{jyZnNCVkeHUh?=
human RPMI-7951 cell NVnqWpRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlTKTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUe5OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5zN{izJO69VQ>? MVPTRW5ITVJ?
human T47D cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2HISGlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlIzPDNizszN NX;SWVhPW0GQR1XS
human A549 cell MlfCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml\UTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlgyOSEQvF2= M3vBSXNCVkeHUh?=
human A2780 cell NYfSNWF1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XEN2lvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU45OjJ3IN88US=> Ml7CV2FPT0WU
human SK-MEL-24 cell MoLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XzTGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? MoLhV2FPT0WU
In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.

4 mg/mL

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Drug: VX-702 Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor